| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/06/2005 | US20050004067 Methods and compositions for inhibiting the function of polynucleotide sequences |
| 01/06/2005 | US20050004066 Monoclonal antibodies specific to VEGF receptors and uses thereof |
| 01/06/2005 | US20050004065 Hypoxia regulated genes |
| 01/06/2005 | US20050004056 Ptp10d, tec protein tyrosine kinase and edtp homologous proteins involved in the regulation of energy homeostasis |
| 01/06/2005 | US20050004055 Synergistic process; electrical stimulation; administering hyaluronidase |
| 01/06/2005 | US20050004051 Methods for treatment of bacterial infections in impaired renal patients |
| 01/06/2005 | US20050004050 for treating Gram-positive bacterial infection of skin and soft tissue; remains at therapeutic levels in the bloodstream for 7 days or longer |
| 01/06/2005 | US20050004043 Protease inhibitors; human t-cell leukemia virus; aids |
| 01/06/2005 | US20050004042 Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif |
| 01/06/2005 | US20050004041 Obtained by hydrolysis of casein; hypotensive agents; foods, drugs |
| 01/06/2005 | US20050004040 Peptide having an affinity for gp120 |
| 01/06/2005 | US20050004038 Therapy for drug resistant cancer, malaria,hematopoiesis |
| 01/06/2005 | US20050004037 Osteogenic growth oligopeptides as stimulants of hematopoiesis |
| 01/06/2005 | US20050004036 Using angiotensin peptides; therapy for ulcer caused by allergens, human immunodeficiency virus, herpes virus infections; stresses; traumas |
| 01/06/2005 | US20050004035 Antiinflammatory agents; multiple sclerosis; inflamamtory bowel disorders; antitumor agents; sepsis |
| 01/06/2005 | US20050004034 Human C-Maf compositions and methods of use therefor |
| 01/06/2005 | US20050004033 Antitumor agents; angiogenesis inhibitors; using polypeptide |
| 01/06/2005 | US20050004032 COMPRISING TRIPEPTIDE UNIT OF THE FORMULA (flp-Yaa-Gly)N, WHERE Yaa IS ANY AMINO ACID, FLP IS 4(R)-FLUORO-L-PROLINE, AND N IS AT LEAST 3; INCREASED STABILITY; STRONGER TRIPLE HELIX THAN NATIVE COLLAGEN; FOR USE SUCH AS IN ARTIFICIAL SKIN |
| 01/06/2005 | US20050004030 Degradation spores; infection therapy |
| 01/06/2005 | US20050004029 Methods and compositions for treating vascular leak using hepatocyte growth factor |
| 01/06/2005 | US20050004028 modulating cell growth, cell differentiation, or cell survival; genetic engineering using hedgehog genes and proteins; neurodegenerative diseases; tissue-targeted therapy |
| 01/06/2005 | US20050004026 Induction of capacse cascade ; administering apoptosis inducing protein; drug screening; anticancer agents |
| 01/06/2005 | US20050004025 Modulation of acetylcholine receptors; central nervous system disorders; schizophenia; skin disorders; Alzheimer's and Parkinson's disease |
| 01/06/2005 | US20050004024 Methods of treating Pin1 associated disorders by covalent modification of active site residues |
| 01/06/2005 | US20050004023 Prevention of hyperinsulinemia in subjects undergoing growth hormone (GH) treatment |
| 01/06/2005 | US20050004022 Cognition activators; neuropathic pain; contacting cells with erythropoietin protein |
| 01/06/2005 | US20050004021 Enzyme inhibitor for therapy of thrombosis, blood disorders |
| 01/06/2005 | US20050004020 Anchoring compound to surface of target cells; protease inhibitors |
| 01/06/2005 | US20050004019 Neuroprotective peptides and uses thereof |
| 01/06/2005 | US20050004018 Use of antitumoral compound in cancer therapy |
| 01/06/2005 | US20050004017 Antiproliferative agents; anticarcinogenic agents |
| 01/06/2005 | US20050004016 Quantitative analysis of amino acid sequences; genetic engineering |
| 01/06/2005 | US20050004015 Novel haemopoietin receptor and genetic sequences encoding same |
| 01/06/2005 | US20050004014 New compound |
| 01/06/2005 | US20050004013 Selective R-cadherin antagonist and methods |
| 01/06/2005 | US20050004012 Use of aplidine for the treatment of pancreatic cancer |
| 01/06/2005 | US20050004011 Compositions and methods for treating bacterial infections with protein-dalbavancin complexes |
| 01/06/2005 | US20050004009 Peptidomimetic inhibitors of STAT activity and uses thereof |
| 01/06/2005 | US20050004007 Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
| 01/06/2005 | US20050004006 Using transferrins as tool in reducing concentration of serum glucose, blood pressure, obesity or glycosylated hemoglobins; antidiabetic agents |
| 01/06/2005 | US20050004005 Methods of treating diseases responsive to Induction of Apoptosis |
| 01/06/2005 | US20050004004 Administering compound capable of binding to cholesterol |
| 01/06/2005 | US20050003999 Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
| 01/06/2005 | US20050003998 Therapeutic use of selective LXR modulators |
| 01/06/2005 | US20050003997 Reduce body mass; obesity therapy; hyperlipemia; insulin resistance; atherosclerosis; antidiabetic agents; hypotensive agents |
| 01/06/2005 | US20050003546 Viral uptake into cells and tissues |
| 01/06/2005 | US20050003503 Microbulbifer culture for use in the generation of agarase and chitinase for use in mixture for treatment and prevention of bacterial infection |
| 01/06/2005 | US20050003492 Novel polypeptide |
| 01/06/2005 | US20050003491 Secreted proteins and polynucleotides encoding them |
| 01/06/2005 | US20050003490 Immunoglobulins specific for cell surface protein for use in diagnosis, prevention and treatment of cell proliferative disorders; inhibitory action associated with reduced cellular transport of amino acids |
| 01/06/2005 | US20050003488 Polypeptide, cDNA encoding the same, and use of them |
| 01/06/2005 | US20050003487 Chordin dorsalizing and hemoglobin inducing polypeptides and nucleic acids encoding the same |
| 01/06/2005 | US20050003484 Modified antigen-presenting cells |
| 01/06/2005 | US20050003483 Major histocompatibility complex peptide ligand for use in identifying modulators which prevent transplantation and autoimmunity disorders; immunotherapy |
| 01/06/2005 | US20050003481 Novel glutamic acid receptor and utilization thereof |
| 01/06/2005 | US20050003480 Tumor necrosis factor variant for use in the treatment and prevention of cell proliferative disorders |
| 01/06/2005 | US20050003477 Expression vector comprising nucleotide sequences coding brain cyclic nucleotide gated ion channel (BCNG) protein for use in treatment and prevention of nervous system, urogenital and cardiovascular disorders |
| 01/06/2005 | US20050003475 Soluble interleukin-20 receptor |
| 01/06/2005 | US20050003466 Mimetic amino acid sequences for use in prevention and treatment of cell proliferative disorders |
| 01/06/2005 | US20050003465 Monoclonal abtibody specific to prostate cell-surface antigen associated with androgen-dependent and androgen-independent prostate tumors for use in prevention, diagnosis and treatment of cell proliferative disorders; immunodiagnostics; immunotherapy |
| 01/06/2005 | US20050003457 Immunoglobulin which binds osteoclastogenesis inhibitory factor binding molecules (OBM)) and prevents bone resorption for use in treatment and prevention of bone disorders |
| 01/06/2005 | US20050003453 G-CSF analog compositions and methods |
| 01/06/2005 | US20050003452 Fusion protein comprising membrane translocation sequences for use in identifying modulators for treatment and prevention of cell proliferative disorders |
| 01/06/2005 | US20050003451 Immunoglobulin for use in diagnosis, prevention and treatment of infection, autoimmune, inflammatory and cell proliferative diseases; immunotherapy |
| 01/06/2005 | US20050003448 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 01/06/2005 | US20050003447 Cell matrix protein for use in diagnosis, treatment and prevention of cell proliferative, autoimmune, inflammatory, vesicle trafficking, neurological, cell motility, reproductive,and muscle disorders. |
| 01/06/2005 | US20050003442 Delta4-desaturase genes and uses thereof |
| 01/06/2005 | US20050003437 Human oncogene induced secreted protein I |
| 01/06/2005 | US20050003433 Recombinant neospora antigens and their uses |
| 01/06/2005 | US20050003431 Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| 01/06/2005 | US20050003427 Dendritic enriched secreted lymphocyte activation molecule |
| 01/06/2005 | US20050003425 Nucleotide sequences coding tumor marker protein for use in diagnosis and/or prognosis of cell proliferative disorders |
| 01/06/2005 | US20050003424 Nucleotide sequences coding ligand-binding receptor polypeptide for use in treating and preventing male sterility; for identifying modulators which can be used as male contraceptives |
| 01/06/2005 | US20050003412 Protein activator of superoxide production for use in treatment and prevention of cancer, psoriasis, prostatic hypertrophy, benign prostatic hypertrophy and cardiovascular disease |
| 01/06/2005 | US20050003404 Telomerase interference |
| 01/06/2005 | US20050003400 Using osteoprotegrin binding agent as tool in identifying modulator for treatment and prevention of osteoporosis and bone disorders |
| 01/06/2005 | US20050003397 Peptide useful in immunomodulation |
| 01/06/2005 | US20050003391 Bioassay for detection of receptor activated nuclear factor kappa beta ligand (RANKL); identifying modulator immune and inflammatory response |
| 01/06/2005 | US20050003385 Diagnosing nervous system disorders via presence of mutation/polymorphism in parkin gene |
| 01/06/2005 | US20050003370 Expression vector comprising nucleotide sequences coding membrane receptor proteins for use in identifying modulators for treatment and prevention of cell proliferative, nervous system, reproductive cardiovascular and inflammation disorders |
| 01/06/2005 | US20050003368 Cancer monitoring and therapeutics |
| 01/06/2005 | US20050003345 Synthetic antigens for the detection of antibodies to hepatitis C virus |
| 01/06/2005 | US20050003003 Modulation of release from dry powder formulations |
| 01/06/2005 | US20050002988 Nutritional composition for controlling blood sugar level |
| 01/06/2005 | US20050002986 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 01/06/2005 | US20050002981 Reducing or preventing restenosis; administering nucleic acid encoding extracellular superoxide dismutase |
| 01/06/2005 | US20050002966 Attenuated pestiviruses |
| 01/06/2005 | US20050002960 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 01/06/2005 | US20050002959 Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| 01/06/2005 | US20050002955 Acquired Immune Deficiency Syndrome (AIDS) diagnosis and treatment |
| 01/06/2005 | US20050002944 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 01/06/2005 | US20050002938 To screen for inhibitors of cell growth and to develop small molecule therapeutics for treating cancers |
| 01/06/2005 | US20050002937 Anti-IL-12 antibodies, compositions, methods and uses |
| 01/06/2005 | US20050002936 Methods and compositions useful for inhibition of angiogenesis |
| 01/06/2005 | US20050002935 Use of B7-H3 as an immunoregulatory agent |
| 01/06/2005 | US20050002933 Proliferation and/or differentiation of stem and progenitor cells from embryo or adult |
| 01/06/2005 | US20050002932 Alleviation of symptoms associated with inflammatory disease states |
| 01/06/2005 | US20050002931 GBS toxin receptor |
| 01/06/2005 | US20050002928 Treatment with anti-ErbB2 antibodies |
| 01/06/2005 | US20050002927 Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |